Brenntag, a global leader in chemicals and ingredients distribution, has signed a strategic partnership with Evonik REXIM to distribute its GMP-grade amino acids to pharmaceutical and biopharmaceutical customers in Europe.
Effective 1 July 2026, the agreement covers most European markets, including the DACH region, the UK, France, Benelux, Scandinavia, CEE, Israel and Turkey, excluding Italy, Ukraine, the Middle East and Africa.
Amino acids are essential components of proteins and play a key role in biochemical and metabolic processes.
REXIM offers highly purified natural and non-natural amino acids and derivatives for regulated applications, including medical nutrition, pharmaceutical APIs and excipients, and cell culture media for biopharma production.
Evonik REXIM is a leading supplier of high-quality amino acids, with relevant parts of its production supported by domestic European supply.
The company combines expertise in fermentation, bioconversion and synthetic manufacturing. The partnership with Brenntag supports Evonik REXIM’s strategy to expand in key global markets while giving customers stronger local service, technical support and long-term supply security.
“Our collaboration with Evonik reflects Brenntag’s commitment to bringing high-value pharmaceutical ingredients and solutions closer to customers,” said Joakim Rehné, President, Brenntag Pharma EMEA.
“By combining Evonik’s expertise in GMP amino acids with Brenntag’s market presence, technical capabilities and regulatory know-how, we are well positioned to support pharmaceutical and biopharmaceutical manufacturers across the region.”
“Our partnership with Brenntag significantly strengthens Evonik REXIM’s market reach,” said Thomas Hermann, Head of the REXIM product line at Evonik Health Care.
“Brenntag’s regional footprint, customer relationships and life-science experience make it an ideal partner. Together, we can provide reliable access to high-quality GMP amino acids and support fast-growing pharmaceutical and biopharmaceutical markets.”
